ASTER DM HEALTHCARE LTD.
NSE : ASTERDMBSE : 540975ISIN
CODE : INE914M01019Industry : Hospital & Healthcare ServicesHouse
: Private
BSE350.050.55 (+0.16 % )
PREV CLOSE (Rs.) 349.50
OPEN PRICE (Rs.) 349.65
BID PRICE (QTY) 349.50 (2 )
OFFER PRICE (QTY) 350.00 (174 )
VOLUME 1697
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE350.00 0.4 (+0.11 % )
PREV CLOSE(Rs.) 349.60
OPEN PRICE (Rs.) 350.00
BID PRICE (QTY) 350.00 (4989 )
OFFER PRICE (QTY) 350.90 (150 )
VOLUME 1040
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 24-Apr-2024 | Aster DM Healthcare informs about compliance certificate | <div>Aster DM Healthcare has informed that compliance certificate issued by Practicing Company Secretary, pertaining to transfer of shares and issue of share certificates for the Financial Year ended March 31, 2024.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 18-Apr-2024 | Aster DM Healthcare, MIMS to acquire 26% stake in Oyster Green Hybrid Two | <p style="text-align: justify;">Aster DM Healthcare (Aster) and Malabar Institute of Medical Sciences (MIMS), a material subsidiary of Aster DM Healthcare, have signed a definitive agreement on April 17, 2024, to acquire 26% stake in Oyster Green Hybrid Two. </p><p style="text-align: justify;">Aster and MIMS intend to meet a part of its total electricity requirement at its Facility through renewable sources of electrical energy and has accordingly approached the Power Producer to set up a captive solar power plant. Pursuant to mutual discussions, Oyster Green Hybrid Two has agreed to build, develop, install, commission, operate, manage, and maintain a 18 MWp captive solar power plant at the Project Site at Kerala. </p><p style="text-align: justify;">Aster and MIMS will purchase 100% of the net output electricity generated. As per the Electricity Act, not less than twenty six percent of the ownership is to be held by the captive user. The acquisition is pursuant to statutory requirement. The transaction is expected to complete on or before December 2024. Cost of acquisition is Rs 7 crore. </p><p style="text-align: justify;">Aster DM Healthcare operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals and clinics, pharmacies, diagnostic centers, educational institutions, and healthcare management and healthcare support systems.</p><div style="text-align: justify;"><br></div> |
| 18-Apr-2024 | Biocon, Aster DM Healthcare and Sunteck Realty to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Biocon </span>has signed an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialization of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes. Under the terms of this agreement, Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.</p><p style="text-align: justify;"><span style="font-weight: bold;">Aster DM Healthcare</span> (Aster) and Malabar Institute of Medical Sciences (MIMS), a material subsidiary of Aster DM Healthcare has signed a definitive agreement on April 17, 2024, to acquire 26% stake in Oyster Green Hybrid Two. Aster and MIMS intends to meet a part of its total electricity requirement at its Facility through renewable sources of electrical energy and has accordingly approached the Power Producer to set up a captive solar power plant; Pursuant to mutual discussions, Oyster Green Hybrid Two has agreed to build, develop, install, commission, operate, manage, and maintain a 18 MWp captive solar power plant at the Project Site at Kerala. </p><p style="text-align: justify;"><span style="font-weight: bold;">Sunteck Realty'</span>s pre-sales stood at Rs 678 crore in Q4FY24 as compared to Rs 537 crore in Q4FY23 i.e. up by 26.25% on yearly basis. On quarterly basis, pre-sales were up by 49% over Rs 455 crore in Q3FY24. However, the company's collections were down by 10.30% to Rs 296 crore in Q4FY24 against Rs 330 crore year-on-year (Y-o-Y) in Q4FY23. On quarterly basis, it declined 32.42% over collections of Rs 438 crore in Q3FY24.</p><p style="text-align: justify;"><span style="font-weight: bold;">Happiest Minds Technologies </span>has developed an innovative GenAI chatbot ‘hAPPI' for Happiest Health. The new GenAI chatbot is developed by its Generative AI Business Services (GBS) unit. A groundbreaking Generative AI-powered chatbot, poised to redefine the way individuals engage in health and wellness knowledge conversations, hAPPI represents a significant advancement in providing personalized and informative interactions for users in the healthcare domain.</p><p style="text-align: justify;"><span style="font-weight: bold;">Bharti Airtel</span> has registered significant increase in 5G users across various States. The company has 5.9 million customers enjoying 5G service in the state of Tamil Nadu, 3 million customers in the state of Gujarat and 1.2 million customers in the state of Jammu, Kashmir and Ladakh. The company has registered a significant increase in 5G users in the past 6 months in various States. The Company's expansive network deployment has effectively extended its services across the entire states, greatly simplifying the process for customers to embrace 5G.</p><p style="text-align: justify;"><span style="font-weight: bold;">Zomato</span> has introduced India's first large order fleet, designed to serve orders for a gathering of up to 50 people for group events like parties. Such large orders were earlier served by multiple regular fleet delivery partners.</p><p style="text-align: justify;"><span style="font-weight: bold;">Sonalis Consumer Products</span> has received a Work Orders worth of Rs 35.10 crore from the MWH Multi Foods for the purpose of Serving Prime Light Food Refreshment Snacks i.e. Puff (Aloo Patty). The Order duration is to be completed within 12 Months from the April 20, 2024. </p> |
| 15-Apr-2024 | Aster DM Healthcare informs about disclosure | <p style="text-align: justify;">Aster DM Healthcare has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 05-Apr-2024 | Dividend Announcement | Interim Dividend & Special Dividend & Inter alia to: 1. consider declaration of interim dividend for the financial year 2023-24 2. consider declaration of special dividend on account of segregation of the GCC business through the sale by Affinity Holdings Pvt Ltd, a wholly owned material subsidiary of the Company of entities conducting business in the GCC region to Alpha GCC Holdings Limited. |
| 04-Apr-2024 | Aster DM Healthcare concludes separation of India, GCC businesses | <p style="text-align: justify;">Aster DM Healthcare has completed the separation of its India and GCC businesses. Under the separation plan, a consortium of investors led by Fajr Capital, a sovereign-backed private equity firm, has acquired a 65% stake in Aster GCC, with the Moopen family retaining a 35% stake alongside management and operational rights. In the Indian operations, the Moopen family continues to hold the 41.88% stake. The transaction has now concluded and pursuant to which Affinity Holdings (a wholly subsidiary of the Company) has received a cash consideration of $907.6 million.</p><p style="text-align: justify;">In November 2023, the Company obtained board approvals to separate its GCC and India businesses to establish two distinct regional healthcare champions that will benefit from the strategic and financial flexibility to meet the priorities of patients and focus on the growing demand in their respective markets. The separation plan was also approved by the Company's shareholders in January 2024. The transaction was subject to customary regulatory approvals, contractual approvals and closing conditions, all of which have been satisfied and concluded.</p><p style="text-align: justify;">Aster DM Healthcare operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals and clinics, pharmacies, diagnostic centers, educational institutions, and healthcare management and healthcare support systems.</p><div style="text-align: justify;"><br></div> |
| 04-Apr-2024 | Aster DM Healthcare climbs after concluding separation of India, GCC businesses | <p style="text-align: justify;">Aster DM Healthcare is currently trading at Rs. 454.80, up by 36.65 points or 8.76% from its previous closing of Rs. 418.15 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 423.00 and has touched a high and low of Rs. 467.55 and Rs. 422.50 respectively. So far 275927 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 495.15 on 28-Feb-2024 and a 52 week low of Rs. 237.00 on 05-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 467.55 and Rs. 402.85 respectively. The current market cap of the company is Rs. 22717.85 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 41.88%, while Institutions and Non-Institutions held 48.15% and 9.97% respectively.</p><p style="text-align: justify;">Aster DM Healthcare has completed the separation of its India and GCC businesses. Under the separation plan, a consortium of investors led by Fajr Capital, a sovereign-backed private equity firm, has acquired a 65% stake in Aster GCC, with the Moopen family retaining a 35% stake alongside management and operational rights. In the Indian operations, the Moopen family continues to hold the 41.88% stake. The transaction has now concluded and pursuant to which Affinity Holdings (a wholly subsidiary of the Company) has received a cash consideration of $907.6 million.</p><p style="text-align: justify;">In November 2023, the Company obtained board approvals to separate its GCC and India businesses to establish two distinct regional healthcare champions that will benefit from the strategic and financial flexibility to meet the priorities of patients and focus on the growing demand in their respective markets. The separation plan was also approved by the Company's shareholders in January 2024. The transaction was subject to customary regulatory approvals, contractual approvals and closing conditions, all of which have been satisfied and concluded.</p><p style="text-align: justify;">Aster DM Healthcare operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals and clinics, pharmacies, diagnostic centers, educational institutions, and healthcare management and healthcare support systems.</p> |
| 03-Apr-2024 | Aster DM Healthcare informs about disclosure | <p style="text-align: justify;">Aster DM Healthcare has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 28-Mar-2024 | Aster DM Healthcare informs about disclosure | <p style="text-align: justify;">Aster DM Healthcare has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Olympus ACF & PACs.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 15-Mar-2024 | Aster DM Healthcare informs about disclosure | <div style="text-align: justify;">Aster DM Healthcare has informed that the exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 14, 2024 for Union Investments.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </div> |
